




















































The aim of this project was to develop a PK model that
can describe the relationships among plasma, saliva and
urinary scopolamine concentrations, using data collected
from the IND clinical trial with INSCOP, and estimate the






































































































































Mean CV% Mean CV% Mean CV% 
Ka1 1/hr 0.34 74.3 0.42 69.3 0.37 47.2
Ka2 1/hr 0.72 68.3 0.81 63.2 0.93 57.5
Kpout 1/hr 0.59 43.6 0.69 38.4 0.61 29.7
Kel 1/hr 0.01 24.3 0.01 28.3 0.01 21.6
Ksout 1/hr 0.17 39.8 0.1 40.9 0.12 34.1
Vmax ng/hr 1698 118.6 1579 89.2 1701 77.8
Km pg/mL 137.2 71.9 127.7 47.5 158.3 58.4
K21 1/hr 1.57 97.5 1.5 89.5 1.1 84.9
V1 L 597 43.2 821 64.7 639 57.1
V2 L 41.5 87.2 37.4 56.1 29.3 35.4
Model 
No. Model description AIC
1p 
Plasma, saliva and urine( SCOP and SCOP-G)
102751 compartment of plasma; Kps and Ksp for saliva
2p
Plasma, saliva and urine (SCOP)
1024.51 compartment of plasma; Kps and Ksp for saliva
3p
Plasma, saliva and urine (SCOP)
1022.71 compartment , Kpout for plasma; Kps and Ksp for saliva
4p
Plasma, saliva and urine (SCOP)
9761 compartment, Kpout for plasma; Kps,Ksp and Ksout for saliva
5p*
Plasma, saliva and urine (SCOP)
902.7
1 compartment, Kpout for plasma
Ka, Vmax, Km,Ksp and Ksout for saliva
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